What is TVGN's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.04B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for TVGN?

P/E (TTM) is n/a and 52-week range is $3.64 to $39.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s TVGN figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for TVGN?

The company profile lists net income (TTM) near $-29M, EPS (TTM) near $-6.80 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Tevogen Bio Holdings Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Warren, New Jersey, US, 4.2M shares outstanding, ISIN US88165K2006 when available from company profile and filing metadata.

Tevogen Bio Holdings Inc

$TVGN

Health Care · Biotechnology

Run Scenarios

$6.78

-3.97%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Tevogen Bio Holdings, Inc. is a clinical-stage specialty immunotherapy company, which engages in the provision of off-the-shelf therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company is headquartered in Warren, New Jersey and currently employs 18 full-time employees. The company went IPO on 2021-11-04. The firm is harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs), to develop off-the-shelf, genetically unmodified precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders, aiming to address the unmet needs of patient populations. Its first product candidate, TVGN 489, has developed to fill a critical gap in COVID-19 therapeutics for the immunocompromised and the high-risk elderly, with potential applications in both treatment and prevention of chronic lingering symptoms of the disease. Its TVGN 601 is being developed for multiple sclerosis (MS), and its TVGN 930 is being developed for EBV-associated lymphomas.

Employees

Website

tevogen.com/

IPO

2021-11-04

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US88165K2006

Headquarters

Warren, New Jersey, US

Shares outstanding

4.2M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

1.66%

Tevogen Bio Holdings Inc (TVGN) Stock Analysis & Quote